Iran-U.S. Peace Deal Near as Oil Prices Fall and Nuclear Disputes Persist 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Trump Signals Possible U.S.-Iran Peace Deal as Markets Rally on Hopes of War Ending 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Gold Prices Hold Firm as Iran Tensions and Dollar Swings Drive Safe-Haven Demand 
China-Made Fireworks Power U.S. Independence Day Celebrations Amid Trade Truce 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
S&P 500, Nasdaq Hit Record Highs as AI Stocks Rally and Strong Jobs Data Boost Confidence 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
Asian Stocks Slide as Iran Tensions Escalate Despite Strong Weekly Gains 
European Stocks Edge Higher as Iran-U.S. Peace Talks Boost Market Sentiment 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
China Export Growth Surges in April as Global Buyers Rush to Secure Supplies 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Samsung Biologics contradicted reports that it will be producing Pfizer’s coronavirus vaccine. There were news going around saying the South Korean biotechnology company headquartered in Incheon is set to start the production of the said American pharmaceutical corp’s COVID-19 vaccine soon.
False manufacturing deal report?
As per The Korea Herald, Samsung Biologics said that the report that was published by the Korea Economic Daily was “not factual.” In the report, it was claimed that the Korean firm is in talks with Pfizer for a manufacturing deal.
An unnamed source from the government allegedly said, “If all goes well, the company will be able to begin mass production of the vaccine in August at the earliest.”
However, Samsung Biologics is saying there is no such deal and not even a discussion about any contract to produce the vaccines for Pfizer. Besides, the American pharma company does not appear to have a problem in producing huge amounts of vaccine doses by itself.
In fact, Bloomberg reported just last week that Pfizer and BioNTech can produce as many as 3 billion doses of their coronavirus vaccine in this year alone. This is said to be more than double the number that the company’s partners had predicted six months ago.
What’s more, Pfizer and BioNTech are reportedly further increasing their production capacity for next year. They are aiming to manufacture more than 3 billion vials of the vaccine. The boost in production comes as the demand has also surged around the world.
Pfizer also deny production outside of its manufacturing lines
It was reported that Pfizer is exclusively manufacturing its own vaccine in its two dedicated supply lines located in Europe and the U.S. The doses made here are for global distribution.
“At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine,” Pfizer said. “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available.”
Meanwhile, South Korea is one of the countries that are waiting for deliveries of Pfizer vaccines. It was said that the Korean government has a contract with the vaccine maker for the supply of 66 million doses of its COVID-19 vaccine.
